nach oben

Erschienen in:

01.08.2020 | Research Article

Targeting Phosphatidylethanolamine with Fluorine-18 Labeled Small Molecule Probe for Apoptosis Imaging

verfasst von: Gongjun Yuan, Shaoyu Liu, Hui Ma, Shu Su, Fuhua Wen, Xiaolan Tang, Zhanwen Zhang, Jing Zhao, Liping Lin, Xianhong Xiang, Dahong Nie, Ganghua Tang

Erschienen in: Molecular Imaging and Biology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Externalization of phosphatidylethanolamine (PE) in dying cells makes the phospholipid an attractive target for apoptosis imaging. However, no ideal PE-targeted positron emission tomography (PET) radiotracer was developed. The goal of the study was to develop a novel PE-targeted radiopharmaceutical to imaging apoptosis.

Procedure

In this study, we have radiolabeled PE-binding polypeptide duramycin with fluorine-18 for PET imaging of apoptosis. Al[¹⁸F]F-NOTA-PEG₃-duramycin was synthesized via chelation reaction of NOTA-PEG₃-duramycin with Al[¹⁸F]F. PE-binding capacity of Al[¹⁸F]F-NOTA-PEG₃-duramycin was determined in a competitive radiometric PE-binding assay. The pharmacokinetic profile was evaluated in Kunming mice. The apoptosis imaging capacity of Al[¹⁸F]F-NOTA-PEG₃-duramycin was evaluated using in vitro cell uptake assay with camptothecin-treated Jurkat cells, along with in vivo PET imaging using erlotinib-treated nude mice.

Results

The total synthesis procedure lasted for 30 min, with a decay-uncorrected radiochemical yield of 21.3 ± 2.6 % (n = 10). Compared with the control cells, the binding of Al[¹⁸F]F-NOTA-PEG₃-duramycin with camptothecin-induced apoptotic cells resulted in a tripling increase. A competitive radiometric PE-binding assay strongly confirmed the binding of Al[¹⁸F]F-NOTA-PEG₃-duramycin to PE. The biodistribution study showed rapid blood clearance, prominent kidney retention, and low liver uptake. In the in vivo PET/CT imaging, Al[¹⁸F]F-NOTA-PEG₃-duramycin demonstrated 2-fold increase in erlotinib-treated HCC827 tumors in nude mice.

Conclusion

Considering the facile preparation and improved biological properties, Al[¹⁸F]F-NOTA-PEG₃-duramycin seems to be a promising PET tracer candidate for imaging apoptosis in the monitoring of cancer treatment.

Nur mit Berechtigung zugänglich

Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305:626–629CrossRef

Meiler J, Schuler M (2006) Therapeutic targeting of apoptotic pathways in cancer. Curr Drug Targets 7:1361–1369CrossRef

Allen AM, Ben-Ami M, Reshef A et al (2012) Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with ¹⁸F-ML-10. Eur J Nucl Med Mol Imaging 39:1400–1408CrossRef

Blankenberg FG, Kalinyak J, Liu L et al (2006) ^99mTc-HYNIC-Annexin V SPECT imaging of acute stroke and its response to neuroprotective therapy with anti Fas ligand antibody. Eur J Nucl Med Mol Imaging 33:566–574CrossRef

Kartachova M, van Zandwijk N, Burgers S et al (2007) Prognostic significance of ^99mTc-Hynic-rh-Annexin V scintigraphy during platinum based chemotherapy in advanced lung cancer. J Clin Oncol 25:2534–2539CrossRef

Oborski MJ, Laymon CM, Lieberman FS et al (2014) First use of ¹⁸F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy. Brain Behav 4:312–315CrossRef

Zeng W, Wang X, Xu P, Liu G, Eden HS, Chen X (2015) Molecular imaging of apoptosis: from micro to macro. Theranostics 5:559–582CrossRef

Challapalli A, Kenny LM, Hallett WA et al (2013) ¹⁸F-ICMT-11, a caspase-3-specific PET tracer for apoptosis: biodistribution and radiation dosimetry. J Nucl Med 54:1551–1556CrossRef

Dubash SR, Merchant S, Heinzmann K et al (2018) Clinical translation of [¹⁸F]ICMT-11 for measuring chemotherapy-induce caspase 3/7 activation in breast and lung cancer. Eur J Nucl Med Mol Imaging 45:2285–2299CrossRef

10.

Zhao M (2011) Lantibiotics as probes for phosphatidylethanolamine. Amino Acids 41:1071–1079CrossRef

11.

Johnson SE, Li Z, Liu Y et al (2013) Whole-body imaging of high-dose ionizing irradiation induced tissue injuries using ^99m Tc-duramycin. J Nucl Med 54:1397–1403CrossRef

12.

Elvas F, Vangestel C, Pak K, Vermeulen P, Gray B, Stroobants S, Staelens S, Wyffels L (2016) Early prediction of tumor response to treatment: preclinical validation of ^99mTc-duramycin. J Nucl Med 57:805–811CrossRef

13.

Liu Z, Larsen BT, Lerman LO, Gray BD, Barber C, Hedayat AF, Zhao M, Furenlid LR, Pak KY, Woolfenden JM (2016) Detection of atherosclerotic plaques in ApoE-deficient mice using ^99mTc-duramycin. Nucl Med Biol 43:496–505CrossRef

14.

Audi SH, Jacobs ER, Zhang X et al (2017) Protection by inhaled hydrogen therapy in a rat model of acute lung injury can be tracked in vivo using molecular imaging. Shock 48(4):467–476CrossRef

15.

Medhora M, Haworth S, Liu Y et al (2016) Biomarkers for radiation pneumonitis using noninvasive molecular imaging. J Nucl Med 57:1296–1301CrossRef

16.

Li Y, Liu C, Xu X, Lu X, Luo J, Gray B, Pak KY, Cheng J, Zhang Y (2018) [^99mTc]duramycin, a potential molecular probe for early prediction of tumor response after chemotherapy. Nucl Med Biol 66:18–25CrossRef

17.

Zhao M, Li Z (2012) A single-step kit formulation for the ^99mTc-labeling of HYNIC-duramycin. Nucl Med Biol 39:1006–1011CrossRef

18.

Wang L, Wang F, Fang W et al (2015) The feasibility of imaging myocardial ischemic/reperfusion injury using ^99mTc-labeled duramycin in a porcine model. Nucl Med Biol 42:198–204CrossRef

19.

Yao S, Hu K, Tang G et al (2015) Positron emission tomography imaging of cell death with [¹⁸F]FPDuramycin. Apoptosis 19:841–850CrossRef

20.

McBride WJ, Sharkey RM, Karacay H et al (2009) A novel method of ¹⁸F radiolabeling for PET. J Nucl Med 50:991–998CrossRef

21.

Luan X, Huang Y, Gao S, Sun X, Wang S, Ma L, Teng X, Lu H, Yu J, Yuan S (2016) ¹⁸F-alfatide PET/CT may predict short-term outcome of concurrent chemoradiotherapy in patients with advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging 43:2336–2342CrossRef

22.

Wu J, Wang S, Zhang X et al (2018) ¹⁸F-Alfatide II PET/CT for identification of breast cancer: a preliminary clinical study. J Nucl Med 59:1809–1816CrossRef

23.

Liu T, Liu C, Xu X et al (2019) Preclinical evaluation and pilot clinical of Al¹⁸F-PSMA-BCH for prostate cancer imaging. J Nucl Med. https://doi.org/10.2967/jnumed.118.221671

24.

Lieberman BP, Ploessl K, Wang L et al (2011) PET imaging of glutaminolysis in tumors by ¹⁸F-(2S, 4R)4-fluoroglutamine. J Nucl Med 52:1947–1955CrossRef

25.

Perreault A, Richter S, Bergman C et al (2016) Targeting phosphatidylserine with a ⁶⁴Cu-labeled peptide for molecular imaging of apoptosis. Mol Pharm 13:3564–3577CrossRef

26.

Zhao M, Li Z, Bugenhagen S (2008) ^99mTc-labeled duramycin as a novel phosphatidylethanolamine-binding molecular probe. J Nucl Med 49:1345–1352CrossRef

27.

Yao S, Hu K, Tang G et al (2015) Molecular PET imaging of cyclophosphamide induced apoptosis with ¹⁸F-ML-8. Biomed Res Int 317403. https://doi.org/10.1155/2015/317403

28.

Rix A, Drude NI, Mrugalia A et al (2019) Assessment of chemotherapy-induced organ damage with Ga-68 labeled duramycin. Mol Imaging Biol:1–11. https://doi.org/10.1007/s11307-019-01417-3

29.

Bernard-Gauthier V, Lepage ML, Waengler B, Bailey JJ, Liang SH, Perrin DM, Vasdev N, Schirrmacher R (2018) Recent advances in ¹⁸F radiochemistry: a focus on B - ¹⁸F, Si - ¹⁸F, Al -¹⁸F, and C - ¹⁸F radiofluorination via spirocyclic iodonium ylides. J Nucl Med 59:568–572CrossRef

30.

Palmieri L, Elvas F, Vangestel C et al (2018) [^99mTc]duramycin for cell death imaging: impact of kit formulation, purification and species difference. Nucl Med Biol 56:1–9CrossRef

31.

Elvas F, Vangestel C, Rapic S, Verhaeghe J, Gray B, Pak K, Stroobants S, Staelens S, Wyffels L (2015) Characterization of [^99mTc]duramycin as a SPECT imaging agent for early assessment of tumor apoptosis. Mol Imaging Biol 17:838–847CrossRef

32.

Da Pieve C, Allot L, Martins CD et al (2016) Efficient ¹⁸F-AlF radiolabeling of ZHER3:8683 affibody molecule for imaging of HER3 positive tumors. Bioconjug Chem 27:1839–1849CrossRef

33.

González Trotter DE, Meng X, McQuade P, Rubins D, Klimas M, Zeng Z, Connolly BM, Miller PJ, O'Malley SS, Lin SA, Getty KL, Fayadat-Dilman L, Liang L, Wahlberg E, Widmark O, Ekblad C, Frejd FY, Hostetler ED, Evelhoch JL (2017) In vivo imaging of the programmed death ligand 1 by ¹⁸F PET. J Nucl Med 58(11):1852–1857CrossRef

34.

Piotrowska Z, Sequist LV (2016) Treatment of EGFR-mutant lung cancers after progression in patients receiving first-line EGFR tyrosine kinase inhibitors: a review. JAMA Oncol 2:948–954CrossRef

35.

Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol 13:239–246CrossRef

36.

Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735–742CrossRef

37.

Hu S, Kiesewetter DO, Zhu L, Guo N, Gao H, Liu G, Hida N, Lang L, Niu G, Chen X (2012) Longitudinal PET imaging of doxorubicin-induced cell death with ¹⁸F-Annexin V. Mol Imaging Biol 14:762–770CrossRef

38.

Wang MW, Wang F, Zheng YJ, Zhang YJ, Zhang YP, Zhao Q, Shen CK, Wang Y, Sun SH (2013) An in vivo molecular imaging probe (18)F-Annexin B1 for apoptosis detection by PET/CT: preparation and preliminary evaluation. Apoptosis 18:238–247CrossRef

39.

Belhocine T, Steinmetz N, Hustinx R et al (2002) Increase uptake of the apoptosis-imaging agent ^99mTc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 8(9):2766–2774PubMed

40.

Mandl SJ, Man C, Edinger M et al (2004) Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome. Mol Imaging 3(1):1–8CrossRef

41.

Vance JE (2008) Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids. J Lipid Res 49:1377–1387CrossRef

Titel: Targeting Phosphatidylethanolamine with Fluorine-18 Labeled Small Molecule Probe for Apoptosis Imaging
verfasst von: Gongjun Yuan
Shaoyu Liu
Hui Ma
Shu Su
Fuhua Wen
Xiaolan Tang
Zhanwen Zhang
Jing Zhao
Liping Lin
Xianhong Xiang
Dahong Nie
Ganghua Tang
Publikationsdatum: 01.08.2020
Verlag: Springer International Publishing
Erschienen in: Molecular Imaging and Biology / Ausgabe 4/2020
Print ISSN: 1536-1632
Elektronische ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-019-01460-0

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Targeting Phosphatidylethanolamine with Fluorine-18 Labeled Small Molecule Probe for Apoptosis Imaging